Breaking Finance News

A statement released earlier today by Cantor Fitzgerald about Shire PLC (LON:SHP) keeps the target price at 6,300.00GBX

Just yesterday Shire PLC (LON:SHP) traded -0.91% lower at 4,400.00GBX. Shire PLC’s 50-day moving average is 3,937.45GBX and its 200-day moving average is 4,399.41GBX. The last closing price is up -10.92% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 3,246,362 shares of SHP traded hands, up from an average trading volume of 2,603,380

In a report released on 6/21/2017 Cantor Fitzgerald hold steady the stock price target of Shire PLC (LON:SHP) from 6,300.00GBX to 6,300.00GBX reporting a possible upside of 0.43%.

Previously on 6/19/2017, JP Morgan Cazenove reported on Shire PLC (LON:SHP) held steady the target price at 6,000.00GBX. At the time, this indicated a possible upside of 0.38%.

Recent Performance Chart


Shire PLC has 52 week low of 3,603.50GBX and a 52 week high of 5,377.00GBX with a PE ratio of 52.60 and has a market capitalization of 0 GBX.

In addition to Cantor Fitzgerald reporting its stock price target, a total of 18 brokers have issued a research note on the company. The average stock price target is 73.73GBX with 6 brokers rating the stock a strong buy, 16 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Shire PLC (LON:SHP)

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.